Key takeaways
- BPC-157 is a synthetic peptide derived from a protein sequence found in human gastric juice, originally studied for organ protection.
- The evidence is mostly preclinical. One 2025 systematic review of 36 studies found 35 were in animals and only 1 was clinical, so what we know is largely from laboratory and animal models.
- Animal research points to possible roles in tendon, ligament, muscle, and wound healing, with mechanisms involving angiogenesis, growth-factor signaling, and cell migration.
- Human testing is now beginning: a Phase 2 trial in athletes with hamstring strains is recruiting, and an earlier Phase 1 trial reported no adverse effects on safety and pharmacokinetics.
- The human evidence is still early, so claims about BPC-157 in people remain unproven and any use should be weighed with a qualified physician.
What is BPC-157?
BPC-157 is a synthetic peptide made up of fifteen amino acids. Its sequence is derived from a protein region first identified in human gastric juice. The original 1993 work that characterized this body protection compound proposed a stomach stress organoprotection hypothesis, the idea that the peptide might help protect and stabilize tissues under stress.
Today BPC-157 is discussed mostly in connection with soft-tissue repair, particularly tendons, ligaments, and the gut lining. The bulk of what is known about it comes from laboratory and animal research, with human clinical testing only now getting underway. That makes it an early-stage compound with promising signals rather than a settled story.
How it works
The proposed mechanisms for BPC-157 center on wound healing and tissue protection. A 2021 review in Frontiers in Pharmacology outlined several pathways through which the peptide appears to support repair across many tissue types, with effects on blood-vessel formation, growth-factor signaling, and the migration of cells involved in healing.
A 2025 review in Current Reviews in Musculoskeletal Medicine described the molecular detail more specifically. BPC-157 appears to activate VEGFR2 and nitric oxide production through the Akt-eNOS axis, which drives angiogenesis (new blood-vessel growth), and to engage ERK1/2 signaling that supports fibroblast activity along with endothelial and muscle repair. The effect looks most relevant in poorly vascularized tissues such as tendons and the junctions where muscle meets tendon. Because these pathways were mapped mainly in cell and animal models, they describe how BPC-157 is thought to act rather than a proven, reliable effect in people.
What the animal evidence shows
The evidence base is overwhelmingly preclinical. A 2025 systematic review in the HSS Journal looked at BPC-157 in orthopaedic sports medicine and screened 544 articles, narrowing to 36 studies. Of those, 35 were preclinical and only one was clinical. Across the animal models, BPC-157 improved functional, structural, and biomechanical outcomes in muscle, tendon, ligament, and bone injuries, and preclinical safety studies showed no adverse effects across several organ systems.
The individual animal findings sharpen that picture. A 2011 study in the Journal of Applied Physiology reported that BPC-157 accelerated tendon healing, promoting the outgrowth of tendon fibroblasts, improving cell survival under stress, and increasing cell migration through the FAK-paxillin pathway. The 2021 Frontiers review compiled supportive wound-healing findings across a wide range of tissues, from skin and gut to tendon, ligament, muscle, bone, and nerve.
A 2025 narrative review in Current Reviews in Musculoskeletal Medicine weighed this regenerative promise against the small body of human data. It identified only a handful of human pilot studies, covering intraarticular knee pain, interstitial cystitis, and intravenous safety and pharmacokinetics, with no adverse effects reported but no large, well-controlled trials yet.
Human trials now underway
The clinical picture is starting to fill in. An earlier Phase 1 pilot study (NCT02637284, 42 healthy volunteers) tested oral BPC-157 to characterize its safety and how the body absorbs and clears it, the first step any compound takes toward human use.
More directly relevant to the soft-tissue claims, a Phase 2 randomized, double-blind, placebo-controlled trial (NCT07437547, 120 participants) is now recruiting. It is testing whether 14 days of BPC-157 alongside a standardized rehabilitation program speeds recovery from an acute grade II hamstring strain, with co-primary endpoints of time to return to unrestricted sport and the change in MRI-measured injury volume at Day 14. This is exactly the kind of controlled human study the reviews above call for, and its results will say a great deal about whether the animal findings carry over to people.
Where it is being studied
Research interest concentrates on musculoskeletal and soft-tissue healing, with the gut and wound-healing work that traces back to the peptide's original organoprotective characterization. Within that range, the most specific human signals so far are the small pilot studies in intraarticular knee pain and interstitial cystitis, alongside the safety and pharmacokinetic data that the new hamstring-strain trial builds on.
The overall picture is consistent: encouraging animal data, biologically plausible mechanisms, and human confirmation as the missing piece. Whether BPC-157 is appropriate for any individual is a question for a qualified physician after a full assessment.
The evidence
Selected references, each verified against primary sources (PubMed and ClinicalTrials.gov). Explore the full, filterable research library on our Science page.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. BPC-157 is discussed in the context of the published research; inclusion of a study does not imply a guaranteed outcome. Many of these compounds are investigational and not approved for the uses described in all jurisdictions. Any treatment decision should be made with a qualified physician. Individual results vary.